Surface Oncology (NASDAQ:SURF) announced its quarterly earnings data on Tuesday. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.01), MarketWatch Earnings reports. Surface Oncology had a negative net margin of 70.90% and a negative return on equity of 32.89%.
Shares of NASDAQ:SURF opened at $9.28 on Friday. The company has a quick ratio of 11.12, a current ratio of 11.12 and a debt-to-equity ratio of 0.16. Surface Oncology has a 52-week low of $1.38 and a 52-week high of $10.25. The company has a 50 day moving average of $8.15 and a two-hundred day moving average of $5.94. The company has a market capitalization of $370.33 million, a price-to-earnings ratio of -10.55 and a beta of 2.40.
In other Surface Oncology news, insider Robert W. Ross sold 4,000 shares of the stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $10.05, for a total value of $40,200.00. Following the completion of the sale, the insider now owns 101,000 shares of the company’s stock, valued at $1,015,050. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 35.00% of the stock is owned by company insiders.
Surface Oncology Company Profile
Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; SRF388 targeting interleukin 27; and SRF813 targeting CD112R.
Read More: Quiet Period Expirations
Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.